RECURSION PHARMACEUTICALS, INC. (RXRX) [Rocket]

Overview

RECURSION PHARMACEUTICALS, INC. (RXRX)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/12/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
10/11/2023	144	Form 144 - Report of proposed sale of securities:
10/10/2023	144	Form 144 - Report of proposed sale of securities:
10/06/2023	4	Gibson Christopher (CEO) has filed a Form 4 on RECURSION PHARMACEUTICALS, INC.
10/05/2023	4	Borgeson Blake (Director) has filed a Form 4 on RECURSION PHARMACEUTICALS, INC.
10/04/2023	4	Dar Zavain (Director) has filed a Form 4 on RECURSION PHARMACEUTICALS, INC.
10/04/2023	4	CHAVEZ R. MARTIN (Director) has filed a Form 4 on RECURSION PHARMACEUTICALS, INC.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19
Revenues	39.8	10.2	4.0	2.3
Revenue growth	291.5%	156.9%	70.8%
Cost of goods sold	48.3	0.0	0.0	0.0
Gross profit	-8.4	10.2	4.0	2.3
Gross margin	-21.2%	100.0%	100.0%	100.0%
Research and development	155.7	135.3	63.3	45.8
General and administrative	81.6	57.7	25.3	19.0
EBITA	-245.7	-182.5	-84.5	-62.4
EBITA margin	-616.7%	-1792.8%	-2132.5%	-2692.6%
Amortization of intangibles		0.3	0.1
EBIT	-245.7	-182.8	-84.6	-62.4
EBIT margin	-616.7%	-1795.8%	-2135.7%	-2692.6%
Pre-tax income	-239.5	-186.5	-87.0	-61.9
Income taxes	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%
Net income	-239.5	-186.5	-87.0	-61.9
Net margin	-601.0%	-1832.2%	-2196.0%	-2668.3%

Diluted EPS		($1.49)	($3.99)	($2.87)
Shares outstanding (diluted)		125.3	21.8	21.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.